Prognostic value of tumor volume assessment on PSMA PET after [Lu-177]PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0
F. Kind, A. C. Eder, C. A. Jilg, P. E. Hartrampf, P. T. Meyer, J. Ruf, K. Michalski
{"title":"Prognostic value of tumor volume assessment on PSMA PET after [Lu-177]PSMA radioligand therapy evaluated by PSMA PET/CT consensus statement and RECIP 1.0","authors":"F. Kind, A. C. Eder, C. A. Jilg, P. E. Hartrampf, P. T. Meyer, J. Ruf, K. Michalski","doi":"10.1055/s-0043-1766156","DOIUrl":null,"url":null,"abstract":"Ziel/Aim Quantitative assessments of positron emission tomography/computer tomography targeting the prostate specific membrane antigen (PSMA PET/CT) are promising for the evaluation of response to [Lu-177]PSMA radioligand therapy (PSMA RLT). Both the updated PSMA PET/CT consensus statement (CS) [1] as well as the recently introduced Response Evaluation Criteria In PSMA-PET/CT (RECIP 1.0) [2], strongly emphasize the change in whole-body tumor volume as a major response criterion. PSMATV50 [3], based on a 50% threshold of the lesional maximum standardized uptake value, appears to be a promising parameter for whole-body tumor volume determination. In the present study PSMATV50 was used for both CS and RECIP 1.0 in order to assess their predictive value for overall survival (OS).","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"46 1","pages":"0"},"PeriodicalIF":1.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1766156","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 1
Abstract
Ziel/Aim Quantitative assessments of positron emission tomography/computer tomography targeting the prostate specific membrane antigen (PSMA PET/CT) are promising for the evaluation of response to [Lu-177]PSMA radioligand therapy (PSMA RLT). Both the updated PSMA PET/CT consensus statement (CS) [1] as well as the recently introduced Response Evaluation Criteria In PSMA-PET/CT (RECIP 1.0) [2], strongly emphasize the change in whole-body tumor volume as a major response criterion. PSMATV50 [3], based on a 50% threshold of the lesional maximum standardized uptake value, appears to be a promising parameter for whole-body tumor volume determination. In the present study PSMATV50 was used for both CS and RECIP 1.0 in order to assess their predictive value for overall survival (OS).
期刊介绍：
Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar.
Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.
Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.
Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
